Shanay Shah, Director of Shalby, says the company has registered healthy Q1 numbers and adds that the firm expects robust numbers in the coming three quarters as well. He says the Q1 numbers can be taken as the run-rate for the year. He says the company has a capex of Rs 10-15 crore, and adds that the net cash is more than the firm’s debt. Going forward, he says, the focus will be on oncology, neurology, cardiology, dentistry. He expects healthy PAT and EPS growth in FY20.